Replies

"Would like to read it. If you have just the title, that would be great." Logo of cvi Clin Vaccine Immunol. 2013 Mar; 20(3): 319–327. doi: 10.1128/CVI.00636-12 PMCID: PMC3592351 PMID: 23283640 Targeting the “Cytokine Storm” for Therapeutic Benefit Riccardo V. D'Elia,corresponding author Kate Harrison, Petra C. Oyston, Roman A. Lukaszewski, and Graeme C. Clark Author information Copyright and License information Disclaimer Clear input Advanced Help COVID-19 is an emerging, rapidly evolving situation. Get the latest public health information from CDC: https://www.coronavirus.gov . Get the latest research from NIH: https://www.nih.gov/coronavirus. "Nicotine is a nonselective agonist of the α7Ach receptor and is able to suppress the production of proinflammatory cytokines by mimicking the binding of acetylcholine. It has been demonstrated that nicotine can selectively reduce the inflammatory response in a number of infection scenarios, including Legionella pneumophila (54) and Chlamydia pneumoniae (55) infection; however, it is highly unlikely that nicotine will ever be used clinically due to its toxicity, addictive nature, and lack of specificity." That article refers to the following: Result Filters Format: Abstract Send to Clin Exp Immunol. 2006 Oct;146(1):116-23. Nicotine inhibits the production of proinflammatory mediators in human monocytes by suppression of I-kappaB phosphorylation and nuclear factor-kappaB transcriptional activity through nicotinic acetylcholine receptor alpha7.